Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis. Rilonacept is an interleukin 1 inhibitor.
Overview, Related Topics & Entities
Explore the main themes, entities and connections around Rilonacept. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
drug fda pericarditis used treat cryopyrin-associated periodic syndromes including familial cold autoinflammatory syndrome muckle wells interleukin-1 receptor recurrent treatment approved
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Rilonacept | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Rilonacept | ATC code | L04AC04 (WHO) | 1.00 | infobox |
| Rilonacept | CAS Number | 501081-76-1 Y | 1.00 | infobox |
| Rilonacept | ChEMBL | ChEMBL1201830 N | 1.00 | infobox |
| Rilonacept | ChemSpider | none | 1.00 | infobox |
| Rilonacept | DrugBank | DB06372 Y | 1.00 | infobox |
| Rilonacept | Formula | C9030H13932N2400O2670S74 | 1.00 | infobox |
| Rilonacept | KEGG | D06635 | 1.00 | infobox |
| Rilonacept | Legal status | US: ℞-only | 1.00 | infobox |
| Rilonacept | Legal status | EU: Rx-only | 1.00 | infobox |
| Rilonacept | License data | EU EMA: by INN | 1.00 | infobox |
| Rilonacept | License data | US DailyMed: Rilonacept | 1.00 | infobox |
| Rilonacept | Molar mass | 201209.36 g·mol−1 | 1.00 | infobox |
| Rilonacept | Other names | IL-1 Trap | 1.00 | infobox |
| Rilonacept | Routes of administration | Subcutaneous | 1.00 | infobox |
| Rilonacept | Trade names | Arcalyst | 1.00 | infobox |
| Rilonacept | UNII | 8K80YB5GMG | 1.00 | infobox |
| Rilonacept | is a | interleukin 1 inhibitor.Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component | 0.90 | text |
| Rilonacept | is a | first drug approved by the FDA to treat recurrent pericarditis | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.